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CHAPTER 5
A DNAJB chaperone subfamily with high activity to suppress 
toxic protein aggregation
Jurre Hageman*1, Maria A. Rujano*1, Maria A.W.H. van Waarde1, Ron Dirks2, 
Nicolette H. Lubsen2,& Harm H. Kampinga1
1) Department of Cell Biology, Section of Radiation and Stress Cell Biology, University 
Medical Center Groningen, University of Groningen, Groningen, the Netherlands.







Misfolding and aggregation are associated with cytotoxicity in polyglutamine diseases. 
Molecular chaperones have been implied against disease progression although with 
different effects depending on the disease models investigated. A systematic approach 
comparing the efficacy of the different members is currently lacking. In a reverse ge-
netic overexpression screen on the HSP110/HSPH, HSP70/HSPA, HSP40/DNAJA and 
HSP40/DNAJB family, a subfamily of the DNAJB family turned out to be superior in 
the suppression of polyglutamine aggregation and associated toxicity both in mam-
malian cell-lines as well as in an in vivo Xenopus model. Aggregation suppression was 
dependent on a C-terminal serine rich region that was required for formation of a large 
protein complex and the activity of the complex was found to be dependent on the 
activity of histone deacetylases. Aggregation suppression ensured that the misfolded 
proteins were maintained in a degradation competent state, which required a function-
al J-domain suggesting Hsp70 involvement. These complexes might be promising and 
powerful new molecular therapeutic targets for ameliorating the progressive effects of 
neurodegenerative diseases.
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Introduction
Proper folding is essential for a protein to acquire its functional native conformation (1). Stress conditions and mutations in the primary sequence of a protein are causative for misfolding and consequently improper protein-protein interactions, trafficking failures 
and aggregation. Polyglutamine diseases are recognized as diseases of misfolding in which 
the non-native structure of specific proteins give rise to neurodegeneration. These diseases 
are caused by the expansion of a CAG trinucleotide repeat within the open reading frame of 
diverse genes which is translated into an abnormally long polyglutamine tract in the diseased 
proteins (2;3). Clinical features and patterns of neuronal degeneration differ among the dis-
eases but yet important pathogenic characteristics are common: all are progressive, typically 
begin in adulthood and neuronal dysfunction along with neuronal loss progress over 10-30 
years after onset and, are ultimately fatal. Therefore the study of quality control mechanisms 
that may intervene in the cytotoxic events underlying neurodegeneration in polyglutamine 
diseases has been a major area of research in the past decade.
Molecular chaperones form the first line of defence as they can bind to partially unfolded 
polypeptides to prevent their inappropriate interaction with other proteins and hereby pro-
tecting them to form irreversible protein aggregates. Therefore, they have been subject of 
intense research in the area of misfolding diseases. The search for inhibitors or modulators 
of polyglutamine aggregation and toxicity, has been largely focused on the most established 
components of the HSP70 molecular chaperone machine, i.e. HSPA1A, HSPA8, DNAJB1 
and DNAJB2 (4-8). Whereas in most cell models the HSP70 machine reduces the extent of 
polyglutamine aggregation, it is still unclear what the crucial factors are. Especially members 
of the HSP40/DNAJ family seem to be rate-limiting for this effect. However, the actual mem-
bers of the HSP40 family that are effective clearly differ between models (4-6;9). In Drosophila 
models for SCA-1, SCA-3 and Huntington, suppression of disease endpoints were found af-
ter overexpression of HSP70 members (HSPA1A, HSPA8) and especially Hdj-1 (DNAJB1) 
and Hdj-2 (DNAJA1) (6;10-14). Inversely, reducing HSP70 expression enhanced the disease 
phenotype (13-15) suggesting that endogenous, constitutively expressed HSP70 members 
are able to mitigate deleterious effects of the mutant protein. In mouse models of SBMA and 
SCA-1, HSP70 overexpression marginally ameliorate motor and behavioral phenotypes and 
protects against neurodegeneration, however without a clear effect on inclusion formation 
(16-18). In mouse models for Huntington’s disease and SCA-7, minor or no effects of HSP70 
alone or together with Hdj-2 overexpression were found on neurodegeneration or inclusion 
formation (19-21). Yet, in the Huntington’s disease model the pharmacological induction of 
the “entire” heat shock response did delay aggregate formation and altered the detergent 
solubility properties of the polyglutamine aggregates, rendering them more soluble (19). So, 
although there is proof of principle that components of the HSP70 machine can reduce ag-
gregation and pathogenesis in polyglutamine disease, the magnitude of effects, especially for 
Huntington’s disease has been moderate. 
Apart from heat shock proteins, also histone deacetylases (HDACs) and in particular HDAC6, 
have been recently shown to have a protective function in neurodegenerative diseases (22-
25). Although it has been suggested that this may be due to deacetylation of histones and thus 
chromatin modification (26), data are emerging that HDACs may modulate protein handling 
e.g. via modulating tubulin (27;28) and cortactin deacetylation (29) which may affect e.g. 
poly-Q disposal via aggresome formation. In addition, it has been recently shown that chap-
erones such as HSP90 (30) may be functionally modulated by (de)acetylation or interact with 
them (e.g. DNAJB6) (31). 
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In the current study, we performed an overexpression screen using the diverse members 
of the HSP70 machine and their subfamilies in a cell model of Huntington’s disease. We 
identify a subfamily of the DNAJB as the most potent aggregation suppressive mammalian 
chaperones. Our data imply that members of this DNAJB subfamily are present in large mo-
lecular complexes for which the activity is regulated via histone deacetylates. These active 
complexes are able to suppress aggregation of non-foldable proteins and keep non-foldable 
substrates in a state compatible with proteasomal degradation. 
Materials and methods
Cell lines, cell culture and transient transfections
N2A (CCL-131), SH-SY5Y (CRL-2266) and Human embryonic kidney 293 stably express-
ing the tetracycline (tet) repressor (Flp-In T-Rex HEK-293, Invitrogen) were grown in DMEM 
(Gibco) supplemented with 10% foetal bovine serum (Sigma) and 100 units/ml penicillin and 
100µg/ml streptomycin (Invitrogen). Flp-In T-Rex HEK-293 were kept under selective pressure 
for the tetracycline repressor and the Flp-in recombination site by adding 5 µg/ml Blasticidine 
(Sigma) and 100µg/ml of Zeocin (Invitrogen) to the culture medium. Cultures were maintained 
at 37°C and 5% CO2 in a humidified incubator. For transient transfections, cells were grown 
to 50-60% confluence in 35 mm-diameter dishes coated with 0.001% of poly-L-lysine (Sigma) 
and/or on coated coverslips for confocal microscopy analyses. Cells were transfected with a 
total of 1 µg of DNA using Lipofectamine (Gibco) according to the manufacturer instructions. 
For stable tetracycline-inducible HDQ119-eYFP expressing cell lines, cells were co-trans-
fected with pcDNA5/FRT/TO HDQ119-eYFP and the Flp recombinase expressing plasmid 
pOG44 and selected with 100µg/ml Hygromycin. For stable DNAJB8 expressing cell lines, 
cells were transfected with pCDNA3 V5-DNAJB8 and selected using 500 µg/ml neomycin. 
The double stable cell line was made by transfecting the pCDNA3 V5-DNAJB8 vector in the 
pcDNA5/FRT/TO HDQ119-eYFP stable cell line and selecting for hygromycin and neomycin 
positive clones. Stable cell lines were verified for the expression of the transgene by Western 
blot and immunofluorescence. 
Gene cloning 
Detailed information about the plasmids used in this study can be found in supplemental table 
1 and 2. Briefly, tetracycline-inducible HSP expression plasmids were constructed as follows. 
First, the GFP and the V5 tag, harbouring a Kozak consensus ATG initiation codon and lacking 
a stop codon, were cloned in the pcDNA5/FRT/TO vector. Subsequently the coding sequence 
of the different chaperones was amplified using the primers listed in supplemental table 1. As 
a template source, cDNA was made from total RNA as previously described (32). As a source 
of total RNA, QPCR Human reference Total RNA (Stratagene) was used. DNAJB4, DNAJB5 
and DNAJB8 where amplified from cloned full length cDNAs purchased from Open Biosys-
tems (clone ID: DNAJB4: 4340658, DNAJB5: 4684829 and DNAJB8: 5296554). The frag-
ments were cloned in pcDNA5/FRT/TO GFP no stop, and the presence of the correct gene 
was sequenced verified. Protein expression was verified by Western blotting. Subsequently, 
fragments were subcloned to pcDNA5/FRT/TO V5 and pcDNA5/FRT/TO. 
pHDQ119-eYFP driving the expression of a fragment of exon-1 of Huntingtin fused to the 
enhanced yellow fluorescent protein was described before (33). The mRFPruby DNAJB8 ex-
pressing construct was made as follows: The mRFPruby gene (34) was amplified and cloned 
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in pcDNA5/FRT/TO (for primers see supplemental table 1). Subsequently DNAJB8 was sub-
cloned in frame with the mRFPruby gene using the restriction sites described in supplemental 
table 2.
The ataxin 3 fragments were amplified from skin fibroblasts from a heterozygous SCA3 pa-
tient with a 82 glutamines containing expanded allele and a 23 glutamines containing wild type 
allele using primers described in supplemental table 1. Both the wild type and the expanded 
fragment were isolated and cloned in the peYFP-N1 vector (Clontech). peGFP-HDQ23 and 
peGFP-HDQ74 were kindly provided by Dr. David Rubinsztein, Cambridge, UK. The pCR3.1 
AR 24Q and pCR3.1 AR 97Q constructs were kindly provided by Dr. Gen Sobue, Nagoya, 
Japan. 
siRNA mediated knockdown 
siGENOME SMARTpool DNAJB6 siRNA (M-013020-00) was purchased from Darmacon and 
transfected using lipofectamine 2000 (Invitrogen) to a final concentration of 50 nM. 
Site directed mutagenesis and generation of deletion mutants 
Site-directed mutagenesis was done using the QuickChange Site-Directed mutagenesis kit 
(Stratagene) according to the protocol of the manufacturer. Primers used are listed in sup-
plemental table 1. 
Deletion mutants were constructed as follows. First, the whole plasmid lacking the deletion 
fragment was amplified by inverse PCR. Thereafter, the parental DNA was cleaved by DpnI, 
the PCR product was phosphorylated by T4 polynucleotide kinase (Invitrogen) and self-ligat-
ed by T4 ligase (invitrogen) and transformed. All mutations were verified by sequencing and 
expression was verified by Western blot analysis.
Semi-quantative RT-PCR 
Total RNA was extracted using the Absolutely RNA isolation kit (Stratagene) from the following 
cell lines: HEK-293 (CRL-1573), HeLA (CCL-2), A549 (CCL-185), HepG2 (HB-8065), SHSY5Y 
(CRL-2266) and VH-25 (primairy human foreskin fibroblasts). QPCR reference RNA, post 
mortem human liver RNA and post mortem human brain RNA were purchased from Strata-
gene. First strand cDNA was prepared as previously described (32). PCR conditions were: 2 
min 94°C, followed by 30 sec 94°C, 30 sec 55°C and 30 sec 72°C and samples were taken 
after 20, 25 and 30 cycles. Primers used are listed in table 1. PCR fragments were cloned and 
sequence verified. To study the inducibility of transcription by heat, the cells where heated for 
30 minutes at 45°C and incubated for another 3 hours at 37°C before total RNA isolation.
Quantitative PCR
Relative changes in transcript level were determined on the Icycler (BioRad) using SYBR 
green supermix (Bio-Rad) as previously described (32). Primers were designed with Perl 
primer. Calculations were done using the comparative CT method according to User Bulletin 2 
(Applied Biosystems). For each set of primers, the PCR efficiency was between 90 and 105%. 
Primer sequences are listed in supplemental table 1.
Cell extracts and sample preparation 
24 or 48 hours after transfection cells were recovered by trypsinization, pelleted and resus-
pended in 1 ml of PBS. The cell suspension was centrifuged at 6000 rpm for 5 min at RT and 
the pellet was resuspended in 75-100 µl of RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 
1% NP-40, 1% sodium deoxycholate, 2% SDS plus protease inhibitors) and sonicated. Pro-
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tein content was determined with the DC protein assay (Bio-RAD). Western blot samples were 
prepared at a final concentration of 1 µg/µl in SDS-PAGE loading buffer and heated for 5 min 
at 100 ºC. Filter trap samples were prepared at a final concentration of 100 ng/µl, 20 ng/µl and 
4 ng/µl in FTA buffer (10 mM Tris-Cl pH 8.0, 150 mM NaCl and 50 mM dithiothreitol) + 2% SDS 
and heated for 5 min at 100 ºC. Samples were used immediately or kept frozen at -20ºC.
Western blot analysis 
Equal amounts of protein were loaded on 10% or 12,5% SDS-PAGE gels. Proteins were 
transferred onto nitrocellulose membranes and probed with mouse anti-GFP antibody JL-8 
(Clontech) at a 1:5000 dilution, mouse anti-V5 antibody (Invitrogen) at a 1:5000 dilution, rabbit 
AR (N20) antibody (Santa Cruz) at a 1:2000 dilution. GAPDH was used a loading control and 
was detected with a mouse antibody (RDI Research Diagnostics) at a 1:10000 dilution. Blots 
were subsequently incubated with HRP-conjugated anti-mouse secondary antibody (Amer-
sham) at 1:5000 dilution and visualization was performed with Enhanced Chemiluminescence 
and Hyperfilm (ECL, Amersham).
Filter trap assay 
To determine protein aggregates, the filter trap assay was performed as previously described 
(35). Briefly, 10, 2 and 0.4 µg of protein extracts were applied onto 0,2 µm pore Cellulose 
Acetate membrane prewashed with FTA + 0.1% SDS. Mild suction was applied and the mem-
brane was washed 3 times. Aggregated proteins trapped in the membrane were probed with 
mouse anti-GFP antibody JL-8 (Clontech) at a 1:5000 dilution and mouse anti-V5 antibody 
(Invitrogen) at a 1:5000 dilution followed by HRP-conjugated anti-mouse secondary antibody 
(Amersham) at 1:5000 dilution. Visualization was performed using enhanced chemilumines-
cence and Hyperfilm (ECL, Amersham). For quantitave analysis, relative intensity of the bands 
was measured using GelPro Analyzer 4.5 gel analyzer software. 
Immunolabelling and confocal microscopy 
16-24 hours after transfection indirect immunofluorescence of the V5 tag was performed to 
detect the chaperones. Cells were fixed with 3.7% formaldehyde for 15 minutes, washed 
three times with phosphate-buffered saline (PBS), permeabilized with 0.2% Triton-X100 and 
blocked during 30 minutes with 0.5% BSA and 0.1% glycine in PBS. Incubation with mouse 
anti-V5 monoclonal antibody (Invitrogen) 1/100 dilution was performed overnight at 4ºC fol-
lowed by a 1 hour incubation with CY5-conjugated anti-mouse secondary antibody (Jackson) 
at 1:200 dilution. Aggregates were visualized using the eGFP tag. To visualize nuclei, cells 
were stained 10 minutes with 0.2 µg/ml 4’,6-diamidino-2-phenylindole (DAPI). Coverslips were 
mounted in Citifluor. Images of eYFP, CY5, and DAPI fluorescence were obtained using the 
Leica confocal laser scanning microscope (Leica TCS SP2, DM RXE) with a 63X/1.32 oil lens. 
The captured images were processed using Leica Confocal Software and Adobe Photoshop.
Time lapse imaging 
Life recordings were performed at the the UMCG Microscopy and Imaging Center. Transfected 
cells were grown in Lab-Tek II (Nalge Nunc) chambers for 18 hours. The slide was transferred 
to a temperature and gas-controlled incubator (37°C and 5% CO2) on the microscope stage of 
a Solamere Nipkow spinning disk CLSM based on a Leica DM IRE2 Inverted microscope with 
a 40x/1,25 oil lens. Images were made in 5 optical planes of 4 microns every 5 min for a period 
of 12 hours. Excitation of eGFP was performed with a 488 nm Argon laser and emission was 
measured with a 525 / 50 CWL / BW (nm) filter. mRFPruby was excited with a 568 nm laser 
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and emission was measured with a 645 / 75 CWL / BW (nm) filter. After imaging, movies of a 
single optimal plane were built using ImageJ 1.37. The movies were compressed using the 
Cinepak codec in Virtual Dub 1.7.1.
Flow cytometry 
For short time viability assays, propidium iodide (PI, 1 µg/ml, Sigma-Aldrich) was added to 
the cells 48 and 96 hours after poly-Q expression. Cells were collected and analyzed by flow 
cytometry on a FACS Calibur flow cytometer (Becton Dickinson, Erembodegem Germany) 
counting 10,000 cells in each group. The percentage of dead cells was calculated from the 
percentage of poly-Q expressing, GFP positive cells that incorporate the dye (GFP + / PI +).
Immunoprecipitation assay
Cells were trypsinized and washed with PBS. The cell pellet was harvested in 0.5 ml of ice 
cold lysis buffer containing 150 mM NaCl, 50 mM NaH2PO4, 10 mM imidazole, 0.5% NP-
40 (igepal), 1.5 mM MgCl2, 3% glycerol 0.9 mM DTT and protease inhibitors, pH 8.0. Cells 
were lysed by passage through a 26G needle for 5 times and subsequently centrifuged twice 
at 14000 rpm for 15 minutes. Subsequently, the supernatant was pre-cleared with 10 µl of 
Sepharose-A/G beads (Santa Cruz Biotechnologies) and incubated for 1 hour at 4 °C with 
slow agitation. Next, 50 µl of lysisbuffer containing 1 µg pre-bound antibody to 10 µl Sepha-
rose-A/G beads was added and incubated at 4 °C for 1 hour with slow agitation. Thereafter, 
the beads were washed 4 times with wash buffer containing 300 mM NaCl, 50 mM NaH2PO4, 
20 mM imidazole, 0.5% NP-40 (igepal), 1.5 mM MgCl2, 3% glycerol, pH 8.0. The pellet was 
eluted in 30 µl lysis buffer and 30 µl 2X Laemli samplebuffer and boiled. 10 µl was subse-
quently loaded for Western blot analysis.
Sucrose density gradient fractionation 
Cells from a 35 mm dish were trypsinized washed and lyzed in 200 µl 1ysis buffer pH 8 con-
taining 150 mM NaCl, 50 mM NaH2PO4, 10 mM imidazole, 0.5% NP-40, 1.5 mM MgCl2 and 
3% glycerol. After passing through a 25G gauge needle for 5 times, the lysate was centrifuged 
at 300G for 15 min. Thereafter 4500 µl sucrose gradients containing 10-80% sucrose in 10 
mM tris-hcl pH8, 50 mM NaCl, 5 mM EDTA were loaded with 150 µl lysate of the lysate and 
centrifuged at 100000g for 18 hours in a Sorvall Discovery 90 SE ultra centrifuge using the 
SW55 rotor. Next, fractions of 400 µl were taken and precipitated with an equal volume of 
25% (w/v) trichloroacetic acid. After 30 min incubation on ice, protein was pelleted at 14000 
rpm for 15 min. The pellet was washed twice with 80% acetone, air dried and dissolved in 
30 µl 1% SDS/0.1M NaOH and an equal amount of Laemmli buffer. 10 µl of the sample was 
subsequently loaded for Western analysis.
Survival assay 
For long term toxicity, we used a clonogenic assay. Exponentially growing cells were plated 
in triplicate (200 cells) on 10-cm petri dishes in 10 ml of culture medium containing the ap-
propriate antibiotics and tetracycline to switch on polyQ expression and allowed to grow for 
14 days. The colonies were fixed and stained, and colonies containing >50 cells were scored. 
The number of colonies grown under polyQ expressing conditions was plotted relative to the 
number of colonies without polyQ expression. 
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Proteasome inhibition HDAC inhibition and autoghagy analysis 
Proteasomal activity was inhibited using 10 µM Mg-132 (Z-Leu-Leu-Leu-al) (Sigma) for 12 
hours. For type I and II HDAC inhibition, trichostatin A (TSA) (Sigma) was added to a final con-
centration of 0, 0.1 and 0.5 µM. The HDAC6 specific inhibitor tubacin or the inactive analog 
nitubacin were a kind gift from Dr. Schreiber and described before (36) and were both used at 
a final concentration of 0, 3 or 5 µM. All HDAC inhibitors were used for 24 hours. Thereafter, 
cells were lyzed and processed as described above. The involvement of autophagy was in-
vestigated using ATG5-/- mouse embryonic fibroblasts, kindly provided by Dr. Mizushima (37); 
these cells were transfected using lipofectamine 2000 (Invitrogen) according to the manufac-
tures protocol.
Xenopus laevis recombinant DNA 
The muscle-specific expression vector pCac(A)2+ was made by replacing the CMV promot-
er of the Xenopus vector pCS2+ (38) with the 0.6-kb muscle-specific cardiac actin (Cac) 
promoter (39). Plasmids pCac(A)2+DNAJB1, pCac(A)2+DNAJB6, pCac(A)2+DNAJB8, and 
pCac-Q119-YFP were made by cloning the NotI (Klenow filled-in) - HindIII fragments of, re-
spectively, pcDNA5/FRT/TO V5-DNAJB1, pcDNA5/FRT/TO V5-DNAJB6, pcDNA5/FRT/TO 
V5-DNAJB8, and pQ119-eYFP into the HindIII and StuI sites of pCac(A)2+.
Stable transgenesis of Xenopus laevis 
Expression cassettes consisting of the Cac promoter, polyQ/DNAJ protein coding region, and 
SV40 polyadenylation signal were excised from the pCS2+ vector backbone using SalI and 
NotI, separated via agarose gel electrophoresis and recovered from the agarose slices using 
the GFX gel band purification kit (Amersham, UK). Transgenesis of Xenopus laevis was per-
formed according to Kroll and Amaya (1996) (40) with modifications according to Sparrow et 
al. (2000) (41). In short, 250,000 sperm nuclei were mixed with ~250 ng expression cassette 
(125 ng Q119-YFP and 125 ng DNAJB1, DNAJB6 or DNAJB8), incubated for 15 min at RT 
and diluted in 500 µl sperm dilution buffer (250 mM sucrose, 75 mM KCl, 0.5 mM spermidine 
trihydrochloride, 0.2 mM spermidine tetrahydrochloride, 5 mM MgCl2, pH 7.4). Eggs were 
dejellied in 2% cystein/1 x MMR (1 x MMR: 0.1 M NaCl, 0.02 M KCl, 0.01 M MgCl2, 0.015 
M CaCl2 en 0.5 M HEPES pH 7.5), transferred to 6% Ficoll/0.4 x MMR and injected with 10 
nl of the diluted nuclei/DNA mixture at 17C. Embryos at the 4-cell stage were transferred 
to 6% Ficoll/0.1 x MMR and incubated O/N at 17C. Gastrulae (Nieuwkoop stage 12) were 
transferred to 0.1 x MMR and incubated at 22C. YFP-positive tadpoles were immobilized 
with MS-222 and photographed using an MZ FLIII fluorescence stereomicroscope provided 
with a DC200 camera (Leica microsystems, Switzerland).
Protein alignments 
Primary amino acid alignments were performed in ClustalX2 using the neighbour-joining algo-
rithm and Blosum matrixes at the default settings (42). Bootstrap analysis was performed us-
ing 1000 random number generator seeds and 1000 bootstrap trials. Phylograms were made 
by importing the homology tree output of ClustalX in TreeView (43). 
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Results 
An overexpression screen on members of the HSP70 machine identifies DNAJB6 
and DNAJB8 as the most potent suppressors of polyglutamine aggregation
In humans, the superfamily of molecular chaperones is composed of several members: the 
HSPA/HSP70 protein family for instance, comprises an abundant and highly conserved group 
of 13 members; the DNAJ/HSP40 protein family has over 40 members and the HSP110 fam-
ily has 4 members. Some members of the HSPA and DNAJ families of molecular chaper-
ones have been identified as modulators of aggregation of several polyglutamine containing 
proteins, but so far a systematic study comparing the efficacy of the different members has 
not been performed. To determine which members of the molecular chaperones family of 
proteins can best modulate the aggregation process of polyglutamine expanded proteins, we 
performed an overexpression screen in HEK-293 cells. Cells were transfected with pHDQ119-
eYFP (eGFP-tagged fragment of the exon-1 of the Huntingtin gene containing 119 glutamines) 
together with plasmids encoding tetracycline inducible V5-tagged molecular chaperones. Ex-
pression of the chaperones was induced 2 hours after transfection and cell extracts were 
prepared 22 hours later. Expression of the transfected proteins was confirmed by Western 
blotting (Figure 1A). Expression of HDQ119-eYFP in HEK-293 cells resulted in the formation 
of SDS-insoluble aggregates which were retained in the cellulose-acetate filter (Figure 1B) 
and large cytosolic inclusions (Figure 1C). Overexpression of none of the HSP110 (HSPH), 
HSP70 (HSPA) or DNAJA proteins inhibited polyglutamine aggregation. However, 2 members 
of the DNAJB subfamily, DNAJB6b and DNAJB8, strongly suppressed the formation of SDS-
insoluble aggregates (Figure 1B), and resulted in cells with a diffuse staining pattern of the 
eGFP-HDQ119 (Figure 1C), with only less than 1% of cells showing inclusions whilst 30% 
of cells lacking these DNAJB proteins contained inclusions (data not shown). Due to lack of 
antibodies to be able to examine the expression levels of the transfected chaperones, we had 
to use V5-tagged constructs for the initial screen. However, to discard the possibility that the 
V5-tags affected the properties of the chaperones, we repeated the screen with untagged ver-
sions, with the assumption that the expression levels obtained would be the same as with the 
V5-tagged proteins. The results obtained with the untagged versions were qualitatively com-
parable to those obtained with the V5-tagged chaperones (Supplemental figure 1A and B). To 
verify that the previous observations were not cell type specific, we used the neuroblastoma 
cell lines N2A and SHSY-5Y which additionally, resemble more the disease-related neuronal 
cell type. DNAJB6b and DNAJB8 showed similar effect on polyglutamine aggregation in these 
cells (Supplemental figure 1C).
It has been shown previously that DNAJB1 (alone or together with HSPA1A) can be a sup-
pressor of aggregation of polyglutamine containing proteins (44), but in our screen this effect 
was nearly absent (Figure 1). To test whether this is due to the length of the polyglutamine 
stretch used in the screen (119 glutamines), the peGFP-HDQ74 plasmid, encoding a frag-
ment of the exon-1 of Huntingtin with a polyglutamine stretch of 74 glutamines, was used in 
combination with some members of each family of chaperones. Again, none of the HSP110, 
HSP70 and DNAJA members tested suppressed eGFP-HDQ74 aggregation, but now DNA-
JB1, like DNAJB6 and DNAJB8, largely inhibited polyglutamine aggregation (Supplemental 
figure 1D and E) and inclusion formation (data not shown). These results are consistent with 
other reports that DNAJB1 is capable of suppressing aggregation of expanded polyglutamine 
stretches, and additionally demonstrate that experiments with these “shorter” polyglutamine 
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DNAJB6 and DNAJB8 belong to a highly conserved subfamily within the DNAJB 
family of molecular chaperones
DNAJ proteins can be divided into three subfamilies: DNAJA, DNAJB and DNAJC. Phylo-
genetic analyses on the human DNAJB subfamily revealed that it can be further divided into 
two separate clusters. One cluster shows close homology to the classical DNAJB1 protein 
(HSP40) and the second cluster shows strong homology to DNAJB6 and DNAJB8 (Figure 1D 
and Supplemental figure 2). Effective suppressors of HDQ119-eYFP aggregation were found 
in the DNAJB6/DNAJB8-like cluster of proteins while none of the members in the DNAJB1-like 
cluster of proteins showed effects on large (Q119) polyglutamine aggregation (Figure 1D and 
1B). Yet, some members of the DNAJB6/DNAJB8-like proteins were also inactive. However, 
these proteins were not present in the cytosol (Figure 1D) where HDQ119-eYFP is expressed. 
In fact, e.g. DNAJB6 is expressed as two isofoms, of which only the shorter transcript was 
found to be effective. These two isoforms differ in the C-terminal region: the shorter transcript 
(DNAJB6b) encodes a 241 amino acid protein that is present in both nuclear and cytosolic 
compartments, whereas the longer transcript encodes a protein of 326-amino acids (DNA-
JB6a) that contains an experimentally verified nuclear localization signal (45). When using a 
nuclear targeted polyglutamine containing protein (Figure 2A), DNAJB6a was found to be as 
effective as DNAJB3, DNAJB6b and DNAJB8, which are also present in the nuclear compart-
ment, in preventing aggregation (Figure 2B), in contrast to DNAJB7 which still lacks activity. 
A comparable situation holds true for the two DNAJB2 isoforms: DNAJB2a, which prevents 
polyglutamine aggregation (Figure 1D), is both cytoplasmic and nuclear, whereas the larger 
DNAJB2b isoform is targeted to the cytoplasmic face of the ER by C-terminal geranylgeran-
ylation (46) and is not effective on cytosolic polyglutamine (Figure 1B). These results show 
that this capacity may indeed be a general property of this DNAJB subfamily. In addition these 
results show that the effect of DNAJB2 and DNAJB6 requires compartmental co-localization 
suggesting that an interaction between the chaperone and the polyglutamine protein is re-
quired. Why DNAJB7 is not effective is at this stage unclear, but it may be due to relatively 
low expression/stability of this paralog compared to the other subfamily members (Figure 2B). 
Since DNAJB6b and DNAJB8 have the most potent anti-aggregation capacity in this sub-
family, we decided to focus on these two proteins for subsequent studies.
DNAJB6b and DNAJB8 suppress aggregation of other misfolded proteins
To determine whether the anti-aggregation effect of DNAJB6b and DNAJB8 is substrate spe-
cific, we co-expressed them with two other polyglutamine expanded, disease-associated pro-
  Figure 1. Members of a DNAJB subfamily act as strong suppressors of polyglutamine ag-
gregation. Cells were co-transfected with HDQ119-eYFP and tetracycline inducible V5 tagged members 
of the HSPH/HSP110, HSPA/HSP70 and DNAJ/HSP40 families of molecular chaperones. Two hours 
after transfection, the expression of chaperones was induced in one of the two identical transfections. (A) 
Western blot analysis of cell extracts prepared 24 hours after transfection. High molecular weight (HMW) 
aggregates trapped in the stacking gel and soluble HDQ119-eYFP were assessed with anti-GFP antibod-
ies. Co-expression of molecular chaperones was verified with anti-V5 antibodies. (B) Filter trap assay 
in samples without (-Tet) and with (+Tet) overexpression of molecular chaperones prepared 24 hours 
after cotransfection. Serial five-fold dilutions were loaded on cellulose-acetate membranes and probed 
with anti-GFP antibody. (C) Representative confocal pictures of cells cotransfected with HDQ119-eYFP 
(green) and V5-tagged chaperone members (red). DAPI staining is shown in blue. Bar represents 30 µm. 
(D) Combined Phylogram of aligned DNAJB primary amino acid sequences (left) with aggregation sup-




teins: an eYFP-tagged fragment of ataxin-3 (SCA-82Q; Figure 2C, D and E) and the full length 
androgen receptor (AR-72Q; Figure 2F and G). DNAJB6b and DNAJB8 efficiently reduced the 
extent of aggregation of these other model proteins, including in the case of the AR, the non-
expanded counterpart which also aggregates to some extent (5). Finally, we tested the effects 
of DNAJB6b and DNAJB8 on the heat-induced denaturation and consequent aggregation of 
firefly luciferase. We have shown previously that DNAJB1 can support the HSP70-dependent 
refolding of heat denatured luciferase expressed in mammalian cells (47). As can be seen 
in figure 2H, overexpression of DNAJB6 and DNAJB8 (but also DNAJB1) suppressed the 
formation of high molecular weight aggregates of unfolded luciferase after heat shock. These 
aggregates are rather distinct from those formed by polyglutamine containing proteins, since 
they do not get trapped in the cellulose-acetate membranes used in the filter trap assay and 
they are partially SDS-soluble (they do enter the stacking gel). Interestingly, neither DNAJB6 
nor DNAJB8 enhanced the post-heat refolding rates and yields of the heat denatured luci-
ferase (data not shown). Together these results suggest that DNAJB6b and DNAJB8 are 
rather generic in their anti-aggregation properties but do not support efficient refolding of heat 
denatured luciferase.
DNAJB6 members are not disaggregating chaperones and interact with pre-existing 
inclusions
To test whether DNAJB86 members prevent aggregate formation or also could disaggregate 
already pre-existing aggregates, cells were transfected with HDQ119-eYFP and DNAJB8 and 
the chaperone was switched on either immediately, 24h or 48h after transfection when some 
aggregation already had occurred. Clearly, pre-existing aggregates were not reduced by 
switching on DNAJB8 although further increase in aggregation was indeed prevented (Figure 
3A and B). 
To further analyze the dynamics of aggregate formation of HDQ119-eYFP in the presence and 
absence of DNAJB8, we performed time lapse microscopy in cells expressing HDQ119-eYFP 
and mRFP-DNAJB6b or mRFP-DNAJB8. Although expression of DNAJB8 almost entirely 
abolished aggregation, few cells (< 1%) co-expressing both HDQ119-eYFP and mRFP-DNA-
JB6b or mRFP-DNAJB8 still formed aggregates (Figure 3C). mRFP-DNAJB6b and mRFP-
Figure 2. Aggregation suppression by the DNAJB subfamily was found for various                 
misfolded protein models. (A) Confocal micrographs of nuclear targeted eGFP-HDQ23 and eGFP-
HDQ74. (B) Filter trap analysis (bottom) on nuclear targeted eGFP-HDQ23 and eGFP-HDQ74 aggrega-
tion. Samples were prepared 24 hours after cotransfection. Top panel shows Western Blot for verification 
of the co-expression of the molecular chaperones using anti-V5 antibodies. (C) Confocal micrographs 
of SCA3 fragments from a wild type allele (GFP-SCA3-22Q) and a mutant allele (GFP-SCA3-82Q). (D) 
Western blot analysis of GFP-SCA3 transfected cell extracts prepared 24 hours after transfection. Ex-
pression of GFP-SCA3 was assessed with anti-GFP antibodies. Co-expression of molecular chaperones 
was verified using anti-V5 antibodies. (E) Filter trap analysis on SCA3-22Q and SCA3-82Q aggregation. 
Samples were prepared 24 hours after cotransfection. Serial five-fold dilutions were loaded on cellulose-
acetate membranes and probed with anti-GFP antibody. (F) Western blot analysis of transfected un-
tagged-androgen receptor encoding constructs containing 24 or 74 glutamines. Membranes were probed 
with an anti-androgen receptor antibody. (G) Filter trap assay of transfected androgen receptor containing 
constructs. Samples were prepared 24 hours after cotransfection and membranes were probed with an 
anti-androgen receptor antibody. (H) Western blot analysis of heat denatured luciferase. High molecular 
weight fractions (HMW) in the stacking gel (upper panel) or soluble fraction (middle panel). Luciferase-
eGFP was detected using an anti-GFP antibody. Co-expression of chaperones was verified using an 
anti-V5 antibody. 
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DNAJB8 clearly co-localized with the inclusion (Figure 3C and supplemental movies). These 
data, suggest that direct interaction exist between HDQ119-eYFP and DNAJB6 members.
Next, we decided to investigate the expression patterns of DNAJB6a, DNAJB6b and DNAJB8. 
Semiquantitative RT-PCR on cDNA prepared from total RNA of various cell lines and tissues 
revealed that DNAJB6 was expressed rather ubiquitously (Figure 3D), DNAJB6b always at 
somewhat higher levels than DNAJB6a, consistent with previous reports (9;48;49). DNAJB8 
transcripts were detected only in testis. Additionally, we compared the amount of transcripts 
of the different DNAJB6/DNAJB8-like subfamily members in HEK-293 cells by qPCR. We ob-
served that DNAJB6a/b is the most abundantly expressed, with transcript levels comparable 
to those of DNAJB1, the most abundant DNAJB member in HEK-293 cells (Figure 3E). In 
contrast, transcripts of DNAJB8 were not detected. Similar results were found in the neurob-
lastoma cell line N2A (Figure 3F). 
Since DNAJB6 is constitutively expressed, we performed downregulation experiments using 
siRNA (Figure 3G). Clearly, this downregulation enhanced the aggregation of eGFP-HDQ74 
(Figure 3H) demonstrating that endogenous DNAJB6 is involved in the prevention of aggrega-
tion of misfolded proteins.
DNAJB6 members reduce polyglutamine induced toxicity 
As can be seen from the immunofluorescent images (Figure 1C), most of the polyglutamine 
aggregates were concentrated in single large aggregates adjacent to the nucleus, resembling 
aggresomes (50;51). Indeed, aggregated Huntingtin in HEK-293 cells localizes close to the 
centriole and is ensheated in a cage of vimentin (33) consistent with their classification as 
aggresomes. Previous studies demonstrated that sorting misfolded proteins to aggresomes 
occurs when protein quality control has failed and as such serves as a (secondary) mecha-
nism to protect cells against the more toxic aggregate intermediates (50;52-54). As DNAJB6 
members nearly completely inhibited the formation of aggresomes, one could argue that this 
might result in increased toxicity rather than cellular protection. Moreover, overexpression by 
itself could be associated with toxicity, especially since DNAJB8 is normally not expressed 
(Figure 3D). Therefore, we performed cell viability assays using a Propidium Iodide (PI) ex-
clusion assay. Previously, we showed (33) that HDQ119-eYFP expressed in HEK-293 cells, 
mainly accumulates in aggresomes (80% of cells with aggregates) and, consistent with that 
  Figure 3. DNAJB6-like proteins do not disaggregate preexisting aggregates but do co-local-
ize with aggregates. (A) Western blot confirming expression of chaperones probed with anti-V5 antibody. 
Cells were transfected and chaperone expression was induced at the indicated time points after transfec-
tion. (B) Filter trap assay on preexisting aggregates. Cells were transfected and chaperone expression 
was induced at the indicated time points after transfection.  (C) Time laps imaging of aggregate formation 
and DNAJB6b or DNAJB8 co-localization. For each panel, confocal pictures were shown at the begin-
ning (upper row) or at the end of the formation of the aggregate (lower row). Arrows indicate the position 
of the cellular aggregate. (D) RT-PCR analysis for the DNAJB6a and DNAJB6b isoforms and DNAJB8 
on various cell-lines (left) and various tissues (right). PCR products were taken after various cycles as 
indicated and GAPDH is used as a loading control. DNAJB6 is ubiquitously expressed whereas DNAJB8 
is testis specific. (E) Relative abundance of DNAJB subfamily transcripts determined by qPCR in human 
HEK-293 cells. The percentage of abundance is indicated for each transcript. (F) Relative abundance of 
DNAJB subfamily transcripts determined by qPCR in mouse neuronal 2A (N2A) cells. The percentage of 
abundance is indicated for each transcript. (G) Western blot analysis of mock siRNA treated cells (left) or 
DNAJB6 siRNA treated cells (right). (H) Filter trap assay on DNAJB6 knockdown cells cotransfected with 
eGFP-HDQ74. Samples were prepared 48 hours after transfection. Serial five-fold dilutions were loaded 




being cytoprotective, the percentage of cell death is low at early time points. However, persist-
ent expression of HDQ119-eYFP also causes an overload of this final rescue mechanism in-
dicated by a progressive, albeit still low increase in the fraction of PI positive cells (Figure 4A). 
In cells cotransfected with DNAJB6b or DNAJB8 the fraction of PI positive cells was strongly 
reduced, demonstrating that both proteins inhibit polyglutamine aggregation in a manner that 
also results in protection against polyglutamine induced cytotoxicity. Similar results were ob-
served in the neuroblastoma cell line SHSY-5Y (Figure 4B). We also tested long-term toxicity 
of polyglutamine expression using a colony forming assay on HEK-293 cells stably expressing 
tetracycline-inducible HDQ119-eYFP. Chronic expression of polyglutamine lead to a dose-
dependent decrease in the number of colonies counted 14 days after gene activation (Figure 
4C and D). Long term overexpression of DNAJB8 was well tolerated and did not affect clono-
genicity (Figure 4D, inset) whilst its co-expression with HDQ119-eYFP largely reduced long 
term toxicity associated with polyglutamine expression (Figure 4D). These results suggest 
that DNAJB6b and DNAJB8 function in protein quality control at a stage prior to the formation 
of toxic intermediates and hence, aggresome formation as a secondary defence mechanism 
does not need to be evoked.
DNAJB6 members also modulate polyglutamine aggregation and toxicity in vivo
To test whether DNAJB6 members could also modulate polyglutamine aggregation in vivo, 
we used a novel Xenopus laevis tadpole model of polyglutamine disease. Expression of poly-
glutamine containing Huntingtin under control of a muscle-specific promoter in transgenic lar-
vae lead to developmental-related mortality and those tadpoles that did survive showed many 
inclusions throughout the body (Figure 4E and F). eGFP-tagged, non-expanded Huntingtin or 
GFP alone were not toxic and resulted in diffuse and homogeneous fluorescence in muscle 
fibres (data not shown). Expression of DNAJB6b or DNAJB8 together with HDQ119-eYFP or 
eGFP-HDQ74 in tadpoles also resulted in predominantly diffuse and homogeneous distribu-
tion of the polyglutamine-expanded proteins (Figure 4E and F). Quantitative analyses of these 
data for both HDQ119-eYFP and eGFP-HDQ74 is shown in figure 4G. Whereas DNAJB6b or 
DNAJB8 co-expression strongly reduced the number of transgenic tadpoles with aggregates, 
co-expression of DNAJB1 neither suppressed HDQ119-eYFP/eGFP-HDQ74 aggregation nor 
toxicity (Figure 4G and data not shown). These data are consistent with our cell model and, 
more importantly, show that DNAJB6b/DNAJB8 can also protect in vivo. Moreover, it shows 
Figure 4. DNAJB6-like proteins reduce toxicity and suppress aggregation in vivo.                    
(A) HEK-293 cells were cotransfected with HDQ119-eYFP and chaperones. Two hours after transfec-
tion, chaperone expression was induced and 24 hours later cells were harvested and the percentage of 
propidium iodide (PI) positive cells was measured in the YFP positive fraction using fluorescent-activating 
cell sorting. (B) N2A cells cells were cotransfected with HDQ119-eYFP and chaperones. 24 hours later, 
cells were harvested and the percentage of propidium iodide (PI) positive cells was measured in the YFP 
positive fraction using fluorescent-activating cell sorting. (C) Clonogenic assay of HEK-293 cells stably 
expressing tetracycline inducible HDQ119-eYFP. 200 cells were plated and the expression of HDQ119-
eYFP was induced using the indicated amount of tetracycline. (D) Quantification of clonogenic assays in 
cells stably expressing tetracycline inducible HDQ119-eYFP and DNAJB8 from a constitutive promoter. 
Stable overexpression of DNAJB8 did not alter the clonogenicity (inset). The number of obtained clones 
without HDQ119-eYFP was set to 100%. (E) Transgenic HDQ119-eYFP positive tadpoles were immobi-
lized with MS-222 and analyzed by fluorescence microscopy. (F) Close-up showing diffuse or aggregated 
HDQ119-eYFP expression in muscle fibers.(G) Percentage of aggregate containing HDQ119-eYFP or 
eGFP-HDQ74 transgenic tadpoles with or without the expression of DNAJB chaperones. Number of 
investigated transgenic tadpoles is indicated.
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that the anti-aggregation properties of these proteins are conserved in vertebrates, suggest-
ing a highly evolutionary conserved protective mechanism.
The N-terminal J-domain of DNAJB6b and DNAJB8 contributes only partially to the 
anti-aggregation activity
The most conserved action of nearly all J domain proteins is their ability to enhance the AT-
Pase activity of HSP70 (55;56). For at least DNAJB1, it has already been shown that it pre-
vents aggregation of polyglutamine expanded proteins in the context of the HSP70 machine 
(5;44). To investigate whether DNAJB6 members also can collaborate with HSP70 proteins, 
we first titrated their concentrations to suboptimal levels as full expression already resulted 
in a near to complete inhibition of aggregation. The expression levels and consequent anti-
aggregation effects of DNAJB6b and DNAJB8 could be tightly regulated in a tetracycline-
concentration dependent manner (Supplemental figure 3A). To test for putative synergy with 
HSP70 members, we used 0.074 µg/ml tetracycline (Supplemental figure 3B). Co-expression 
of none of the HSP70 members (Supplemental figure 3B) significantly increased the anti-ag-
gregation effect of DNAJB6b (Supplemental figure 3C), meaning that up-regulation of HSP70 
members is not required for DNAJB6 members to exert their action. To what extent their ac-
tivities rely on constitutively expressed members like HSPA8 or HSPA1A/B was further tested 
using O23 hamster lung fibroblasts which do not express endogenous HSPA1A and HSPA1B 
under normal conditions (47). Also in these cells, DNAJB6b or DNAJB8 completely inhibited 
polyglutamine aggregation (data not shown). Thus, HSPA1A/B is not required for the activity 
of DNAJB6b or DNAJB8. However, it is still possible that other constitutively expressed mem-
bers like HSPA8 (HSC70) are the interaction partners of DNAJB6 members. Down-regulation 
of HSPA8, however, was toxic to cells and therefore could not be tested.
As an alternative approach to test if and how DNAJB6b and DNAJB8 functionally interact with 
the HSP70 machine in suppressing polyglutamine aggregation, we generated a number of 
mutants. The J domain is the major binding site and the minimal region required for interaction 
between the HSP40/DNAJ with HSP70/HSPA. It consists of four α-helices with a loop region 
containing a highly conserved tripeptide of histidine, proline, and aspartic acid (HPD motif) 
(57). For prokaryotic DNAK-DNAJ or eukaryotic HSPA1A-DNAJB1 or HSPA8-DNAJB1, muta-
tions in the HPD motif lead to a loss of their functional cooperation in the refolding of unfolded 
  Figure 5. The J-domain of DNAJB6-like protein facilitates the degradation of polyglutamine 
expanded proteins. (A) Western blot analysis of DNAJB J-domain mutants. (B) Filter trap assay on 
eGFP-HDQ74 transfected cells, coexpressing DNAJB J-domain mutants. Samples were prepared 48 
hours after transfection. Serial five-fold dilutions were loaded on cellulose-acetate membranes and 
probed with anti-GFP antibody. (C) Schematic representation of the DNAJB6b J-domain (upper panel) 
in the DNAJB6 protein and Western blot and filter trap assay on cells coexpressing HDQ119-eYFP and 
J-domain mutants of DNAJB6b (lower panel). (D) Schematic representation of the DNAJB8 J-domain (up-
per panel ) in the DNAJB6 protein and Western blot and filter trap assay on cells coexpressing HDQ119-
eYFP and J-domain mutants of DNAJB8 (lower panel). (E) Western analysis on cells transfected with 
different ratios of DNAJB8 to HDQ119-eYFP or DBAJB8 H/Q to HDQ119-eYFP plasmids. (F) Western blot 
showing expression of transfected HDQ119-eYFP and DNAJB8 in mouse embryonic fibroblasts devoid of 
ATG5. (G) Filter trap assay on HDQ119-eYFP transfected cells with or without coexpressing DNAJB8 in 
ATG5 knockout mouse embryonic fibroblasts. Samples were prepared 24 hours after transfection. Serial 
five-fold dilutions were loaded on cellulose-acetate membranes and probed with anti-GFP antibody. (H) 
Western blot on cells transfected with HDQ119-eYFP, chaperones and treated with DMSO or MG-132 as 
indicated. (I) Filter trap assay on HDQ119-eYFP and DNAJB6b or DNAJB8 transfected HEK-293 cells 
treated with DMSO or MG-132 as indicated. Samples were prepared 24 hours after transfection. Serial 
five-fold dilutions were loaded on cellulose-acetate membranes and probed with anti-GFP antibody.
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substrates (58;59). DNAJB6b and DNAJB8 mutants in which the histidine residue in the con-
served HPD motif of the J-domain was substituted by a glutamine (H/Q) (Figure 5A and B) 
were still fully capable of inhibiting eGFP-HDQ74 aggregation unlike DNAJB1 H/Q (Figure 5A 
and B) (44). However, when a longer polyglutamine tract was used (HDQ119-eYFP), the H/Q 
mutant showed a significant reduction in activity (Figure 5C and D). Furthermore, deletion of 
the complete J-domain also resulted in a similar reduction of the anti-aggregation activity of 
DNAJB6b and DNAJB8 (Figure 5C and D). Additionally, we tested whether BAG1 or CHIP, 
two co-chaperones with antagonistic actions on HSP70/HSPA activity as compared to HSP40/
DNAJ proteins (60-62) would revert the effects of DNAJB6b or DNAJB8 on polyglutamine 
aggregation. Overexpression of both proteins alone had no effect on HDQ119-eYFP aggrega-
tion. However, co-expression of BAG1 or CHIP almost completely abolished the protective 
effect of DNAJB1 whilst the protective effects evoked by DNAJB6b or DNAJB8 were only par-
tially inhibited (Supplemental figure 3D). So, this is similar to what was found for the J-domain 
deletion mutants (Figure 5C and D).
Together, these data suggest that full activity of DNAJB6-like members requires a functional 
J-domain, indicating collaboration with an HSP70 machine. For DNAJB1 and DNAJB2a, it has 
been suggested that they suppress polyglutamine aggregation via an enhancement of HSP70 
dependent (proteasomal) degradation (5;7). To address whether this is also the case for the 
J-domain dependent activity of DNAJB6b and DNAJB8, we co-transfected DNAJB8 or the 
mutant DNAJB8-H/Q together with HDQ119-eYFP in different plasmid ratios and assessed 
soluble HDQ119-eYFP levels by Western blot. Interestingly, the levels of soluble HDQ119-
eYFP decreased with increasing amounts of wild type DNAJB8, whereas such an effect was 
not seen for the DNAJB8-H/Q mutant (Figure 5E). This suggests that DNAJB8 keeps poly-
glutamine containing proteins in a soluble state, competent for degradation in an HSP70 de-
pendent manner. We next tested whether this effect was related to autophagy-related degra-
dation or proteasomal-dependent degradation. In ATG5-/- mouse embryonic fibroblasts which 
are macro autophagy defective (37) (Figure 5F and G), polyglutamine aggregation was slightly 
higher than in ATG5+/+ cells, suggesting that (macro)-autophagy plays a role in the normal 
turnover of the polyglutamine containing protein as has been shown before (63). However, 
DNAJB8 was fully functional in these ATG5-/- cells (Figure 5G), both in terms of suppressing 
aggregation and in reducing the total soluble levels of the polyglutamine expanded Huntingtin 
fragment. This excludes autophagy as the underlying degradation pathway. Next, we used 
MG132 to block proteasomal degradation during expression of DNAJB6b or DNAJB8. Under 
this condition, both the level of soluble polyglutamine proteins (Figure 5H) and their aggrega-
tion increased (Figure 5I). These combined data therefore suggest that DNAJB6 members 
collaborate with the HSP70 machine to facilitate proteasomal degradation of polyglutamine-
containing substrates, hereby reducing the cellular load and thus aggregation propensity of 
these unfolded substrates.
The C-terminus of DNAJB6b and DNAJB8 is crucial for the anti-aggregation activity
Next, we investigated what features specific to the C-terminus of DNAJB6b and DNAJB8 are 
essential in preventing polyglutamine aggregation before the eventual substrate transfer to 
members of the HSP70 family for degradation. The importance of the DNAJB6b/DNAJB8 sig-
nature in the C-terminus was first illustrated by the finding that a DNAJB8-DNAJB1 chimeric 
protein, harbouring the J-domain of DNAJB8 and the C-terminus of DNAJB1, was ineffective 
in suppressing polyglutamine aggregation, whereas the chimera DNAJB1-DNAJB8, harbour-
ing the J-domain of DNAJB1 and the C-terminus of DNAJB8 was fully active (Figure 6A). 
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Figure 6. The C-terminus of DNAJB6-like proteins contains a serine rich region important for ag-
gregation suppression. (A) Schematic representation of chimeric DNAJB1/DNAJB8 proteins (upper 
panel) and Western blot and filter trap assay on cells coexpressing HDQ119-eYFP and chimeric mutants 
of DNAJB1/DNAJB8 (lower panel). (B) Schematic representation of C-terminal DNAJB8 mutants (up-
per panel) and Western blot and filter trap assay on cells coexpressing HDQ119-eYFP and C-terminal 
DNAJB8 mutants (lower panel).
In search for the functional domains within the C-terminus, we generated deletion mutants 
from both the C-terminal and N-terminal end of DNAJB8∆J (Supplemental figure 4A). These 
data revealed that the activity is retained even upon deletion of AA 70-151 and indicated that 
the main activity resides within the 152-232 fragment. Within this fragment a short sequence 
(TTKRIVENGQERVEVEEDGQLKS) could be recognized that was rather conserved in the 
DNAJB6/DNAJB8 subfamily but not in the DNAJB1-like proteins. However, mutants lacking 
this TTK-LKS motif (DNAJB6-ΔTTK-LKS and DNAJB8-ΔTTK-LKS), were still capable of pre-
venting HDQ119-eYFP aggregation, although slightly less efficient than the WT (Figure 6B). 
Sequence alignments further identified a serine-rich region within the DNAJB6/DNAJB8 sub-
family (AA 149-186: SSF-SST) that was also not found in the DNAJB1-subfamily. Deletion 
of this serine-rich region (ΔSSF-SST), lead to a substantial loss of anti-aggregation capacity 
(Figure 6B). Furthermore, combining this mutant with a deletion of the entire J-domain (ΔJ 
ΔSSF-SST) lead to complete loss of function (Figure 6B), demonstrating that for full activity 
DNAJB8 requires both the serine-rich region as well as the J-domain. 
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Formation of high molecular weight complexes and deacetylation events are re-
quired for DNAJB8 anti-aggregation activity
It has been shown for DNAJB1 that the C-terminal domain is involved in the formation of ho-
modimers, and this homodimerization has been proposed to be essential for its function (64). 
To investigate whether functional DNAJB8 was also present as dimers or larger oligomeric 
complexes, we analyzed the electrophoretic mobility of DNAJB8 and DNAJB8 ΔSSF-SST on 
4-16,5% polyacrylamide native gels. DNAJB8 showed a considerably slower migration veloc-
ity compared to DNAJB8 ΔSSF-SST (Figure 7A). On 10-80% sucrose gradients, DNAJB8 was 
found to be present in most fractions, indicating it can exist as a plethora of oligomeric forms 
(Figure 7B). On the contrary, the serine-rich region deletion mutant was recovered only in the 
first 2-3 fractions, indicating that this mutant that lacked anti-aggregation function (Figure 6B) 
had also lost its ability to form oligomeric species. 
Considering that the SSF-SST region in DNAJB8 is both crucial for its function and quaternary 
structure, we reasoned that it must contain key features which are essential for its molecular 
mechanism of aggregation suppression. It has been shown for DNAJB6, that a region be-
tween aminoacids 146 and 177, is responsible for its interaction with HDAC4 (31). Sequence 
analyses indicates that this region in DNAJB6 partially overlaps with the serine-rich region 
deleted from DNAJB8 in the ΔSSF-SST mutant (Figure 7C). Thus, we decided to investigate 
whether DNAJB8 is also able to interact with histone deacetylases and whether this interac-
tion might be involved in the anti-aggregation activity. We used his-tagged DNAJB6b and 
DNAJB8 to pull down a number of co-overexpressed Flag-tagged HDAC’s in the three HDAC 
families of type-I (HDAC1, HDAC3, HDAC8), type II (HDAC4, HDAC5, HDAC6, HDAC7) and 
type III (SIRT-2). Of these tested members, HDAC4, HDAC6, and SIRT2 (but none of the oth-
ers tested) were found to interact with both DNAJB6b and DNAJB8 (data not shown). Next, 
co-immunoprecipitation (IP) analyses revealed that full length DNAJB6b and DNAJB8 indeed 
interacted with HDAC4, HDAC6 and SIRT2 whereas the mutant of DNAJB8 lacking the serine 
rich region lost this capacity (Figure 7D and E), demonstrating that the SSF-SST motif is re-
sponsible for interaction with HDAC’s. DNAJB1, which lacks this SSF-SST motif did not show 
interaction with these HDACs (data not shown). To test whether interaction with these HDACs 
are relevant to the functionality of DNAJB6b and DNAJB8, we treated cells with Trichostatin A 
(TSA), a general inhibitor of class I and II histonee deacetylases. Although TSA did not affect 
Figure 7. DNAJB8 is found in large oligomeric complexes and the activity of the complex 
is dependent on HDAC activity. (A) Native gel electrophoresis of DNAJB8 wt and DNAJB8 serine rich 
region deletion mutants. (B) Sucrose Density Gradient Fractionation of DNAJB8 wt protein and DNAJB8 
serine rich region deletion mutants. Low molecular weight fractions reside in low sucrose containing frac-
tions whereas high molecular weight complexes are found in high sucrose containing fractions. (C) Sche-
matic representation of reported HDAC 4 interactions with DNAJB6b as described by Dai et al. (31) (D) 
Immunoprecipitation assay on DNAJB1, DNAJB6b, DNAJB8 and a serine rich region deletion mutant of 
DNAJB8. HDAC proteins were immunoprecipitated using an anti-FLAC antibody. Subsequently Western 
blots were probed for anti-V5 for the presence of DNAJB proteins. (E) Reverse immunoprecipitation as-
say on SIRT2, HDAC4 and HDAC6. DNAJB proteins were immunoprecipitated using an anti-V5 antibody. 
Subsequently Western blots were probed for anti-FLAC for the presence of HDAC proteins. (F) Western 
analysis of DNAJB8 and HDQ119-eYFP transfected cells treated with Trichostatin A (type I and II HDAC 
inhibitor), Tubacin (HDAC6 specific tubulin deacetylation inhibitor), or Nitubacin (an inactive tubacin ana-
log). The activity of the inhibitors was assessed using an acetylation specific tubulin antibody (anti-AcTub). 
(G) Filter trap assay on HDQ119-eYFP transfected cells coexpressing DNAJB6b or DNAJB8 and treated 
with Trichostatin A, Tubacin or Nitubacin. Samples were prepared 24 hours after transfection. Serial five-
fold dilutions were loaded on cellulose-acetate membranes and probed with anti-GFP antibody. (H) Sche-
matic representation of functionally mapped DNAJB8 regions critical for aggregation suppression. 



























































































































































































































































































































































the oligomeric state of DNAJB8 (data not shown), it did inhibit the anti-aggregation activity of 
DNAJB6b and DNAJB8 in a dose dependent manner (Figure 7F, G and Supplemental figure 
4B, C), suggesting that the deacetylation activity of type I or II HDACs but not of the type III 
HDAC SIRT2 is essential for the DNAJB6/DNAJB8 anti-aggregation function. Since HDAC6 
has been implicated in quality control in polyglutamine models (22;23;65) we subsequently 
used Tubacin, a specific inhibitor of de alpha-tubulin deacetylase activity of HDAC6 (66). 
Although Tubacin, but not its non-functional structural analogue Nitubacin, was effective in 
increasing alpha-tubulin acetylation in the same manner as TSA (Figure 7F), Tubacin did not 
result in inhibition of DNAJB8 activity on HDQ119-eYFP aggregation (Figure 7F and G) sug-
gesting that HDAC6 dependent deacetylation of alpha-tubulin is not required for the activity of 
DNAJB6b and DNAJB8.
Thus, our data show that the anti-aggregation activity of DNAJB6b and DNAJB8 resides in 
two separate domains of the protein which have divergent functions. The J-domain, forms a 
bridge with the HSP70 machine to facilitate degradation, whereas the serine rich region in the 
C-terminal domain is involved in the acquisition of the quaternary architecture of the functional 
complex and requires a type II deacetylase activity, possibly from HDAC4 (Figure 7H).
Discussion
In this manuscript, we describe the results of the first systematic comparative screen for the 
efficacy of different HSPH, HSPA and DNAJ chaperones to suppress polyglutamine aggre-
gation. Members within a subfamily of the DNAJB family were found to act as very potent 
suppressors of poly-glutamine aggregation and superior compared to previously identified 
chaperones (67;68). They act in a very promiscuous manner, preventing aggregation of sev-
eral unrelated substrates. Both in vitro and in vivo the polyglutamine associated toxicity was 
counteracted by the expression of members from the DNAJB subgroup, strongly suggesting 
that these chaperone proteins function upstream of toxic aggregation events. 
Our data point to the existence of an evolutionary conserved chaperone complex specialized 
to deal with non-foldable substrates. Interestingly, two members from the identified subfamily 
have already been described previously as polyglutamine suppressors. This includes DNAJB2 
which was suggested to act by stimulating the proteasomal degradation of expanded poly-
glutamine containing proteins. DNAJB2 was found to interact with ubiquitin moieties on sub-
strates through its ubiquitin interaction motifs (UIMs) (7). However, this UIM motif is not shared 
by the other members of the subfamily (7), implying that this cannot be the crucial feature 
for which most members of the DNAJB6 subfamily share the anti-aggregation capacity. The 
Drosophila ortholog of DNAJB6, MRJ1, has previously been identified in a screen for genetic 
factors that dominantly modify polyglutamine toxicity (69) and recent data demonstrate that 
MRJ1 or DNAJB6 overexpression suppresses exogenous polyglutamine toxicity in various fly 
tissues and human cells respectively (9;70). This is consistent with our findings that DNAJB6 
and DNAJB8 were functional in Xenopus, suggesting strong functional evolutionary conserva-
tion. DNAJB6-like proteins were found in all metazoans analyzed, suggesting a general need 
for an anti-aggregation chaperone. So, what could be the function in normal cell physiology? It 
has been shown that DNAJB6 binds to keratin and prevents its toxic aggregation in chorionic 
trophoblast cells during chorioallantoic attachment in placental development (71;72). As such 
it mediates keratin turnover, which would be consistent with our observations that DNAJB6 
(and DNAJB8) maintain poly-Q proteins in a degradation competent form. The formation of a 
keratin network in trophoblast cells is a key event in the chorioallantoic attachment (73) and 
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consistently, homozygous DNAJB6 mutant mice die due to a failure of chorioallantoic fusion 
(48). 
So what are the special features of this DNAJB sub-family that makes them distinct from e.g. 
DNAJB1-like members or DNAJA proteins that can suppress protein aggregation to some 
extent, but less efficient? Unlike DNAJB6 members, DNAJB1-like members or DNAJA1 can 
also support protein refolding (47;74) suggesting that their interactions with substrates differ. 
Both DNAJB1 and DNAJA1 require dimer formation for their functionality and these dimers 
are thought to enlarge the substrate binding affinity (75). For DNAJB8, we found that it forms 
high molecular weight complexes. Although we have no insight into the possible arrangement 
of the monomers in these oligomeric complexes, it is tempting to speculate that such an oligo-
meric complexes enlarges the exposed surface of the substrate binding area, hereby enhanc-
ing substrate affinity. The functional relevance of DNAJB6-like chaperone oligomerization is 
supported by the finding that deletion of the serine rich stretch in the C-terminus of the protein 
leads to both loss of function and loss of complex formation. 
Interestingly, the serine rich stretch in DNAJB6 members, required for function and oligomeri-
zation, also matches with a HDAC binding motif identified in previous studies (31) and HDAC 
inhibition resulted in loss of activity. HDAC inhibition did not affect the DNAJB8 oligomeric 
structure, implying that complex formation alone is not sufficient for the functionality of DNA-
JB6-like members. Inversely, deletion of the serine rich stretch did lead to loss of interaction 
with HDACs suggesting that HDACs either directly interact with this motif domain or that the 
complex formation is needed for the interaction between HDAC and DNAJB6 members. The 
connection between HDAC activity and activity of DNAB6 members is highly intriguing given 
the suggested roles of HDAC activity in protein quality control (22). In particular, HDAC6 has 
been implemented as a key modulator in determining the fate of cytotoxic proteins by the 
stimulation of aggresome formation (25), proteasomal degradation (76) or autophagy (23). 
HDAC6 forms a complex with SIRT2 (77) and is thought to play a decisive role in the ultimate 
fate of unfolded substrates and thus could be very well linked to the activity of DNAJB6 like 
protein. Yet, the HDAC6 inhibitor tubacin had no effect on DNAJB6-mediated protection. This, 
however, may not fully rule out the importance of HDCA6 in the activity of DNAJB6-like pro-
teins because HDAC6 contains two distinct deacetylation domains. Whereas only one domain 
functions in tubulin deacetylation and can be inhibited by tubacin, the other domain is tubacin 
insensitive (66). Both domains can be inhibited by TSA (66) and as such may explain why 
tubacin did not reduce DNAJB6-like activity. Unfortunately, however, conflicting results regard-
ing the specificity of these domains were reported in subsequent reports (78;79). Whereas the 
TSA data seem to rule out a role for SIRT2, a type III HDAC found to bind to DNAJB6, these 
data suggest that HDAC4, another class II HDAC that binds DNAJB6 and DNAJB8 could also 
be involved in the regulation of DNAJB6 like proteins. At this stage, we are not aware of any 
data linking HDAC4 to neurodegeneration. Thus although the actual HDAC protein involved 
remains unidentified our data point towards the requirement of HDAC activity, most likely a 
type II HDAC protein. 
In addition to the serine rich region, it was found that the J-domain was required for full activ-
ity of the DNAJB oligomeric chaperone complex. The DNAJ domain was found to function as 
a molecular bridge for HSP70-dependent proteasomal degradation. As stated before, most 
members in the DNAJB6 subfamily lack the UIM domain that is found in DNAJB2, suggesting 
this UIM domain is not absolutely required for this transfer mechanism and rather may be a 
typical feature of DNAJB2 specific function. Indeed, also other DNAJ members, like DNAJB1 
support HSP70 dependent degradation for certain clients (5), whereas they support HSP70 
dependent (re)folding for other clients (47). So, it seems that the fate of clients is more de-
pendent on the intrinsic (re)foldability of the client itself. However, the stronger the client af-
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finity of DNAJ members is, the stronger they suppress aggregation and the slower they may 
transfer substrates to the HSP70 machine, allowing more time for the required ubiquitination 
and (HSP70-dependent) recruitment of the proteasome for degradation and/or processing 
by autophagy. Although we did not find a requirement for autophagy for the anti-aggregation 
activity of DNAJB6 members, we cannot exclude at this stage that DNAJB6-substrate com-
plexes cannot also be processed by autophagic routes.
Overall, our data suggest that DNAJB6-like proteins resembles sHSP proteins with a J-do-
main. Formation of oligomeric species of the protein results in active aggregation suppressive 
complexes with high substrate affinity that shield the non-foldable clients for the life time of 
the protein. But, unlike the sHSP that have no known domains to recruit Hsp70 for further 
processing, DNAJB6-like proteins can recruit HSP70 by their J-domain to link the suppressor 
complex to protein degradation machines. As such, they seem to be amongst the strong-
est protectors against protein toxicity associated with protein misfolding diseases and form 
promising and powerful new molecular therapeutic targets for ameliorating the progressive 
neurological detrimental effects of these diseases.
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Supplemental figure 1. Aggregation suppressive activity is similar with untagged chaperone mem-
bers. (A) Western blot analysis of cell extracts prepared 24 hours after transfection. High molecular weight 
(HMW) aggregates trapped in the stacking gel and soluble HDQ119-eYFP were assessed with anti-GFP 
antibodies. (B) Filter trap assay in samples expressing HDQ119-eYFP without and with coexpression of 
molecular chaperones prepared 24 hours after cotransfection. Serial five-fold dilutions were loaded on 
cellulose-acetate membranes and probed with anti-GFP antibody. The aggregation suppressive effects 
were found in neuronal like cell lines (C) N2A and SHSY-5Y were cotransfected with HDQ119-eYFP and 
the chaperones DNAJB1, DNAJB6b and DNAJB8. Western blot analysis for chaperone expression in 
N2A cells using the anti-V5 antibody (left panel) and Filter trap assay (right panel). Serial five-fold dilutions 
were loaded on cellulose-acetate membranes and probed with anti-GFP antibody. DNAJB1 suppresses 
aggregation of eGFP-HDQ74. (D) Western blot analysis of cell extracts prepared 24 hours after trans-
fection. Expression of high molecular weight (HMW) aggregates trapped in the stacking gel and soluble 
eGFP-HDQ74 was assessed with anti-GFP antibodies. (E) Filter trap assay in samples without and with 
overexpression of molecular chaperones prepared 48 hours after cotransfection. Serial five-fold dilutions 
were loaded on cellulose-acetate membranes and probed with anti-GFP antibody.
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                1                                                                        75 
DNAJB2 a    (1) MASYYEILDVPRSASADDIKKAYRRKALQWHPDKNPDNKEFAEKKFKEVAEAYEVLSDKHKREIYDRYGREGLTG 
DNAJB2 b    (1) MASYYEILDVPRSASADDIKKAYRRKALQWHPDKNPDNKEFAEKKFKEVAEAYEVLSDKHKREIYDRYGREGLTG 
DNAJB6 a    (1) MVDYYEVLGVQRHASPEDIKKAYRKLALKWHPDKNPENKEEAERKFKQVAEAYEVLSDAKKRDIYDKYGKEGLNG 
DNAJB6 b    (1) MVDYYEVLGVQRHASPEDIKKAYRKLALKWHPDKNPENKEEAERKFKQVAEAYEVLSDAKKRDIYDKYGKEGLNG 
DNAJB7      (1) MVDYYEVLGLQRYASPEDIKKAYHKVALKWHPDKNPENKEEAERKFKEVAEAYEVLSNDEKRDIYDKYGTEGLNG 
DNAJB8      (1) MANYYEVLGVQASASPEDIKKAYRKLALRWHPDKNPDNKEEAEKKFKLVSEAYEVLSDSKKRSLYDRAGCDSWRA 
                76                                                                      150 
DNAJB2 a    76) TGTGPSRAEAGSGGPGFTFTFRSPEEVFREFFGSGDPFAELFDDLGPFSELQNR-G-----SRHSGPFFTFSSSF 
DNAJB2 b   (76) TGTGPSRAEAGSGGPGFTFTFRSPEEVFREFFGSGDPFAELFDDLGPFSELQNR-G-----SRHSGPFFTFSSSF 
DNAJB6 a   (76) GGGGGSHFDSPFEFG---FTFRNPDDVFREFFGGRDPFSFDFFEDPFEDFFGNRRGPRGSRSRGTGSFFSAFSGF 
DNAJB6 b   (76) GGGGGSHFDSPFEFG---FTFRNPDDVFREFFGGRDPFSFDFFEDPFEDFFGNRRGPRGSRSRGTGSFFSAFSGF 
DNAJB7     (76) GG---SHFDDECEYG---FTFHKPDDVFKEIFHERDPFSFHFFEDSLEDLLNRPGSSYGNRNRDAGYFFSTASEY 
DNAJB8     (76) GGGASTPYHSPFDTG---YTFRNPEDIFREFFGGLDPFSFEFWDSPFNSDRGGR-G-----HGLRGAFSAGFGEF 
                151                                                                     225 
DNAJB2 a  (145) PG----------------------HSDFSSSSFS-FSPGAGAFRSVSTSTTFVQGRRITTRRIMENGQERVEVEE 
DNAJB2 b  (145) PG----------------------HSDFSSSSFS-FSPGAGAFRSVSTSTTFVQGRRITTRRIMENGQERVEVEE 
DNAJB6 a  (148) PSFGSGFSSFDTGFTSFGSLGHGGLTSFSSTSFG--GSGMGNFKSISTSTKMVNGRKITTKRIVENGQERVEVEE 
DNAJB6 b  (148) PSFGSGFSSFDTGFTSFGSLGHGGLTSFSSTSFG--GSGMGNFKSISTSTKMVNGRKITTKRIVENGQERVEVEE 
DNAJB7    (145) PIFEKFSSYDTGYTSQG-SLGHEGLTSFSSLAFD--NSGMDNYISVTTSDKIVNGRNINTKKIIESDQE-REAED 
DNAJB8    (142) PAFMEAFSSFNMLGCSG-----GSHTTFSSTSFGGSSSGSSGFKSVMSSTEMINGHKVTTKRIVENGQERVEVEE 
                226                                                                     300 
DNAJB2 a  (197) DGQLKSVTINGVPDDLALGLELSRREQQPSVTSRSGGTQVQQTPASCPLDSDLSEDEDLQLAMAYSLSEMEAAGK 
DNAJB2 b  (197) DGQLKSVTINGVPDDLALGLELSRREQQPSVTSRSGGTQVQQTPASCPLDSDLSEDEDLQLAMAYSLSEMEAAGK 
DNAJB6 a  (221) DGQLKSLTINGVADDDAL-----AEERMRRGQNALPAQPAGLRPPKPPRPASLLRHAPHCLSEEEGEQDRPRAPG 
DNAJB6 b  (221) DGQLKSLTIN-------------GKEQLLRLDNK----------------------------------------- 
DNAJB7    (216) NGELTFFLVNSVANEEG------FAKECSWRTQSFNNYSPNSHSSKHVSQYTFVDNDEGGISWVTSNRDPPIFSA 
DNAJB8    (212) DGQLKSVTVNGK-------------EQLKWMDSK----------------------------------------- 
                301                                               353 
DNAJB2 a  (272) KPADVF----------------------------------------------- 
DNAJB2 b  (272) KPAGGREAQHRRQGRPKAQHQDPGLGGTQEGARGEATKRSPSPEEKASRCLIL 
DNAJB6 a  (291) PWDPLASAAGLKEGGKRKKQKQREESKKKKSTKGNH----------------- 
DNAJB6 b  (242) ----------------------------------------------------- 
DNAJB7    (285) GVKEGGKRKKKKRKEVQKKSTKRNC---------------------------- 
DNAJB8    (233) ----------------------------------------------------- 
 
 
DNAJB subfamily Mus musculus
DNAJB subfamily Homo sapiens
                1                                                                        75 
 DNAJB3     (1) MVDYYEVLGVPRQASAEAIRKAYRKLALKWHPDKNPEHKEEAERRFKQVAQAYEVLSDVRKREVYDRCGEVGEVG 
 DNAJB6  a  (1) MVDYYEVLGVQRHASPEDIKKAYRKQALKWHPDKNPENKEEAERKFKQVAEAYEVLSDAKKRDIYDKYGKEGLNG 
 DNAJB6  b  (1) MVDYYEVLGVQRHASPEDIKKAYRKQALKWHPDKNPENKEEAERKFKQVAEAYEVLSDAKKRDIYDKYGKEGLNG 
 DNAJB6  c  (1) MVDYYEVLGVQRHASPEDIKKAYRKQALKWHPDKNPENKEEAERKFKQVAEAYEVLSDAKKRDIYDKYGKEGLNG 
 DNAJB7     (1) MVDYYEVLGVQRYASPEDIKRAYRKVALKWHPDKNPENKEEAERKFKEVAEAYEVLSNVEKRDIYDKYGKEGLDG 
 DNAJB8     (1) MANYYEVLGVQSSASPEDIKKAYRKLALRWHPDKNPDNKEEAEKKFKQVSEAYEVLSDSKKRS---VYDRAGCDR 
 DNAJB10 a  (1) MASYYEILDVPRSASPDDIKKAYRKKALQWHPDKNPDNKEFAEKKFKEVAEAYEVLSDR---------------- 
 DNAJB10 b  (1) MASYYEILDVPRSASPDDIKKAYRKKALQWHPDKNPDNKEFAEKKFKEVAEAYEVLSDKHKREIYDRYGREGLTG 
                76                                                                      150 
 DNAJB3    (76) G--GGAAGSPFHDAFQYVFSFRDPAEVFREFFGGHDPFSFDFFGGDPLENFFGDRRSTRGSRS--------RGAV 
 DNAJB6  a (76) G--GGGGGIHFDSPFEFGFTFRNPDDVFREFFGGRDPFSFDFF-EDPFDDFFGNRRGPRGNRS--------RGAG 
 DNAJB6  b (76) G--GGGGGIHFDSPFEFGFTFRNPDDVFREFFGGRDPFSFDFF-GLLGDFHFQAVRIFAQEKK--------LLHG 
 DNAJB6  c (76) G--GGGGGIHFDSPFEFGFTFRNPDDVFREFFGGRDPFSFDFF-EDPFDDFFGNRRGPRGNRS--------RGAG 
 DNAJB7    (76) ---RGAS--HLDDEREYRFTFRKADDVFKEIFGERDPFSFHLF-EDSLEGLLNSSRSPSGSRG--------RGAG 
 DNAJB8    (73) WRAGGGANVPHSSPFGAGYPFRNPEDIFREFFGGLDPFSFEFWDTPFSGRGRPHGLHRVFPSGFGEFPAFMEALS 
 DNAJB10 a (60) --SGPSRSETGGAGPGFTFTFRSPEEFFREFFGSGNPFSELFDDLGVFSELQNQGPR---------------LTG 
 DNAJB10 b (76) AGSGPSRSETGGAGPGFTFTFRSPEEVFREFFGSGDPFSELFDDLGVFSELQNQGPR---------------LTG 
                151                                                                     225 
 DNAJB3   (141) PFSTSFTEFPGFGGGFASLDTGFTSFGSPGNSGLSSFSMSCGGG-AAGNYKSVSTSTEIINGKKITTKRIVENGQ 
 DNAJB6  a(140) SFFSTFSGFPSFGSGFPAFDTGFTPFGSLGHGGLTSFSSTSFGGSGMGNFKSISTSTKIVNGKKITTKRIVENGQ 
 DNAJB6  b(140) YYVYEVTVQPTG---------GFEEVASEDLE----------------------PS------EELDQPCFEESVE 
 DNAJB6  c(140) SFFSTFSGFPSFGSGFPAFDTGFTPFGSLGHGGLTSFSSTSFGGSGMGNFKSISTSTKIVNGKKITTKRIVENGQ 
 DNAJB7   (137) SHVSRAYDHPALSG-LSSYDTGYSSYVSLGHEGLTSFSSLALDDSGMGNYIPITPSGKVINGRNINTKKAFENRQ 
 DNAJB8   (148) SFNTLGHGGGSR-----------STFSSASFGGS-----------GSSGFKSVMSSTEMVNGRKVTTKRIIENGQ 
 DNAJB10 a(118) PFFTFSSSFPAN-----------SDFSSSSFSFSP----------GAGAFRSVSTSTTFVQGRRITTRKIMENGQ 
 DNAJB10 b(136) PFFTFSSSFPAN-----------SDFSSSSFSFSP----------GAGAFRSVSTSTTFVQGRRITTRRIMENGQ 
                226                                                                     300 
 DNAJB3   (215) ERVEVEEDGELKSLIINGREQLLRINTQ----------------------------------------------- 
 DNAJB6  a(215) ERVEVEEDGQLKSLTINGVADENALAEECQRRGQPTPALAPGPAPAPVRVPSQARPLAPTPAPTPAPTPAPAPAQ 
 DNAJB6  b(178) D-ALSDEHSEVLDVISSEELDLSEDESSEGCSWGQGGLLSEDLDLVSSE--EEASLGDAEELSEEYGELLSE--- 
 DNAJB6  c(215) ERVEVEEDGQLKSLTINGKEHLLRLDNK----------------------------------------------- 
 DNAJB7   (211) E-REAEDDSELISFLVNS--VANEEHFTDKCNWRRQSFNNYSPNSYSSSNTTQYTLVDNNEQGTSWVTNKKEPSI 
 DNAJB8   (201) ERVEVEEDGQLRSVTVNGKEKLMRVDK------------------------------------------------ 
 DNAJB10 a(172) ERVEVEEDGQLKSVSINGVPDDLALGLELSRR-EQQPSVAPGLGVMQVRPTSLSRPPDHDLSEDEDLQLAMAYSL 
 DNAJB10 b(190) ERVEVEEDGQLKSVSINGVPDDLALGLELSRR-EQQPSVAPGLGVMQVRPTSLSRPPDHDLSEDEDLQLAMAYSL 
Supplemental figure 2. Primary amino acid alignment of DNAJB6-like members. (A) Human DNAJB6-
like members. (B) Mouse DNAJB6-like members. Primary amino acid alignments were performed using 
the ClustalX2 software package.
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Tet - Tet +
DNAJB6b
Tet - Tet +
DNAJB8
Tet - Tet +
Supplemental figure 3. DNAJB6-like aggregation suppressive effects are dose dependent. (A) 
Western and filter trap assay on cells co-expressing HDQ119-eYFP and DNAJB6b or DNAJB8. Dose de-
pendent expression was induced by the addition of increasing tetracycline amounts as indicated. DNAJB6 
or DNAJB8 do not synergize with overexpressed HSPA proteins. (B) Western blot analysis of cell extracts 
prepared 24 hours after transfection. The expression of chaperones was assessed using the anti-V5 an-
tibody. (C) Filter trap assay in samples without and with overexpression of HDQ119-eYFP together with 
DNAJB1, DNAJB6b or DNAJB8 and various HSPA chaperones. Samples were prepared 24 hours after 
cotransfection. Serial five-fold dilutions were loaded on cellulose-acetate membranes and probed with 
anti-GFP antibody. CHIP and BAG1 completely inhibit DNAJB1 but not DNAJB6b and DNAJB8 in their 
aggregation suppression activity. (D) Filter trap assay in samples expressing HDQ119-eYFP without and 
with coexpression of DNAJB1, DNAJB6b or DNAJB8 together with either CHIP or BAG1. Samples were 
prepared 24 hours after transfection. Serial five-fold dilutions were loaded on cellulose-acetate mem-







































DNAJB8 J SSF DSK
DNAJB8 J FGG DSK
DNAJB8 J ING DSK
DNAJB8 J GST SSF
DNAJB8 J GST GLR
DNAJB8 J GST PFS
DNAJB8 J GST TGY
DNAJB8 J VEE DSK




































-    +Tet
Supplemental figure 4. Systematic deletion analysis for DNAJB8 aggregation suppressive regions. 
(A) Schematic representation of systematic DNAJB8 deletion mutants (upper panel). Filter trap assay on 
samples cotransfected with HDQ119-eYFP and DNAJB1, DNAJB6b or DNAJB8 together with either CHIP 
or BAG1. Samples were prepared 24 hours after transfection. Serial five-fold dilutions were loaded on 
cellulose-acetate membranes and probed with anti-GFP antibody. Dose dependent relationship between 
Trichostatin A and reduction of DNAJB6b or DNAJB8 mediated aggregation suppression. (B) Western 
analysis of samples cotransfected with HDQ119-eYFP and DNAJB6b or DNAJB8 and treated with vari-
ous doses of Trichostatin A as indicated. Samples were prepared 24 hours after transfection and addition 
of Trichostatin A. (C) Filter trap analysis of samples cotransfected with HDQ119-eYFP and DNAJB6b or 
DNAJB8 and treated with various doses of Trichostatin A as indicated. Samples were prepared 24 hours 
after transfection and addition of Trichostatin A. Serial five-fold dilutions were loaded on cellulose-acetate 
membranes and probed with anti-GFP antibody.
An aggregation suppressive DNAJB chaperone subfamily 
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Supplemental movies. DNAJB6b and DNAJB8 colocalize with polyglutamine aggregates. mRFP 
tagged DNAJB6b or DNAJB8 were cotransfected with HDQ119-eYFP and aggregate formation was fol-
lowed using life cell imaging. Left panel represents HDQ119-eYFP expression, middle panel the ex-
pression of mRFP or mRFP tagged DNAJB6b or DNAJB8 and the right panel shows the overlay of 
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